GlassScriptPhysician profile
Laurence Lum
NPI 1932193554
$21,626.84
in general payments reported to CMS, 2019-2025
86 companies · $3,155 in 2025
The $3,155 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,937 · 2020: $1,865 · 2021: $3,298 · 2022: $3,674 · 2023: $3,058 · 2024: $3,641 · 2025: $3,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,708 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,708.31 |
| Education | $145.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,504.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,154.11 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Pfizer INC. | $1,130.70 | 2019-2025 | |
| Lilly USA, LLC | $953.70 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $873.87 | 2019-2025 | Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $781.32 | 2019-2025 | Spravato, Invega Sustenna, Xarelto |
| Novo Nordisk INC | $716.11 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $663.18 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $645.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $550.65 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Allergan, INC. | $539.07 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $494.52 | 2019-2025 | Fanapt, Hetlioz |
| Aimmune Therapeutics, INC. | $494.42 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $461.86 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $446.26 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
Show all 86 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Lum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.